Trial Profile
The Impact of Lixisenatide on Postprandial Glucose Tolerance in Pancreatectomised Subjects -a Delineation of Extrapancreatic Effects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Lixisenatide (Primary) ; Paracetamol
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Acronyms Px-Lixi
- 11 May 2020 Results evaluating whether the glucagon-like peptide 1 (GLP-1) receptor agonist lixisenatide would improve postprandial glucose tolerance in totally pancreatectomised patients, published in the Diabetologia
- 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
- 24 Oct 2016 Status changed from recruiting to completed.